eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Manuscripts accepted About the journal Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
2/2019
vol. 15
 
Share:
Share:
more
 
 
abstract:
Commentary

New antihistamines – perspectives in the treatment of some allergic and inflammatory disorders

Jan Tatarkiewicz, Przemysław Rzodkiewicz, Małgorzata Żochowska, Anna Staniszewska, Magdalena Bujalska-Zadrożny

Arch Med Sci 2019; 15, 2: 537–553
Online publish date: 2019/02/04
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 

Introduction

Histamine [H] is a well-known biogenic amine whose biological properties were first characterized more than 100 years ago [1, 2]. It plays a significant role in the human organism as a mediator and neurotransmitter. Histamine is produced in many types of tissues including immune cells, gastric mucosa, central nervous system (CNS), smooth muscles, sensory nerves, heart, etc. Histamine-producing cells may be divided into two types: professional and non-professional [3]. Professional histamine-producing cells such as mast cells, basophils, enterochromaffin-like cells of the gastric mucosa, and histaminergic neurons synthesize this mediator, collect it in special granules inside the cells and release it in large amounts after specific stimulation. In non-professional histamine-producing cells, histamine is synthesized and crosses the cell membrane with specific carrier proteins according to the concentration gradient. The non-professional histamine-producing cells include many other cell types, among them dendritic cells (DCs) [4] and T cells [5].
Histamine is involved in numerous physiological and pathophysiological processes [6] – immunological response, immunomodulation, inflammation, allergic response, gastric acid secretion, cell proliferation, wound healing, cognitive function, memory, sleep cycle, endocrine homeostasis – and has an influence on release of other neurotransmitters [7] and modulation of tumor growth [8].
Histamine exerts its effect through four types of G-protein coupled receptors: H1, H2, H3, and H4 [6, 7, 9, 10]. Histamine interacts with its receptors with different affinities. The most susceptible are histamine H3 and H4 receptors (H3Rs and H4Rs, respectively), whereas the activation of H1 and H2 receptors (H1Rs and H2Rs, respectively) requires significantly higher concentrations of histamine [11]. It is suggested that in some disorders in which classic antihistamines (i.e. drugs antagonizing histamine effects at H1 receptors) were not effective, it might be possible to control them using novel histamine receptor ligands acting at H3 and/or H4 receptors [6, 12].

Methods of review

The authors searched the electronic database MEDLINE (PubMed, https://www.ncbi.nlm.nih.gov/pubmed/; until January 15th, 2017) using the following population search terms: H3 OR H4 combined using the Boolean operator AND with the term receptor*. These search results were focused by combination using the...


View full text...
references:
Emanuel MB. Histamine and the antiallergic antihistamines: a history of their discoveries. Clin Exp Allergy 1999; 29 Suppl 3: 1-11; discussion 12.
Katzung BG. Histamine, serotonin, and the ergot alkaloids. In: Basic and Clinical Pharmacology. 12th edn. Katzung BG, Masters SB, Trevor AJ (eds). The McGraw-Hill Companies, Inc.. New York 2012; 273-93.
Stegaev V, Sillat T, Porola P, et al. Brief report: first identification of H4 histamine receptor in healthy salivary glands and in focal sialadenitis in Sjögren’s syndrome. Arthritis Rheum 2012; 64: 2663-8.
Szeberenyi JB, Pallinger E, Zsinko M, et al. Inhibition of effects of endogenously synthesized histamine disturbs in vitro human dendritic cell differentiation. Immunol Lett 2001; 76: 175-82.
Mirossay L, Chastre E, Callebert J, et al. Histamine H2 receptors and histidine decarboxylase in normal and leukemic human monocytes and macrophages. Am J Physiol 1994; 267: R602-11.
Panula P, Chazot PL, Cowart M, et al. International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors. Pharmacol Rev 2015; 67: 601-55.
Mahdy AM, Webster NR. Histamine and antihistamines. Anaesth Inten Care Med 2011; 12: 324-9.
Hellstrand K, Hermodsson S, Naredi P, et al. Histamine and cytokine therapy. Acta Oncol 1998; 37: 347-53.
Stark H. Histamine receptor. BIOTREND Reviews 2007; Review No. 1/11-2007. URL: https://www.biotrend.com/download/5BT_Histamine_Review11_07.pdf (last accessed on January 15, 2017).
Wedi B, Wieczorek D, Raap U, Kapp A. Urticaria. J Dtsch Dermatol Ges 2014; 12: 997-1009.
Tiligada E, Zampeli E, Sander K, Stark H. Histamine H3 and H4 receptors as novel drug targets. Expert Opin Investig Drugs 2009; 18: 1519-31.
Cataldi M, Borriello F, Granata F, et al. Histamine receptors and antihistamines: from discovery to clinical applications. Chem Immunol Allergy 2014; 100: 214-26.
Skidgel RA, Kaplan AP, Erdös EG. Histamine, bradykinin, and their antagonists. In: Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 12th edn. Brunton LL (ed.). The McGraw-Hill Companies, Inc., New York, London 2011; 911-35.
Jutel M, Akdis M, Akdis CA. Histamine, histamine receptors and their role in immune pathology. Clin Exp Allergy 2009; 39: 1786-800.
Hill SJ, Ganellin CR, Timmerman H, et al. International Union of Pharmacology. XIII. Classification of histamine receptors. Pharmacol Rev 1997; 49: 253-78.
Haas HL, Sergeeva OA, Selbach O. Histamine in the nervous system. Physiol Rev 2008; 88: 1183-241.
Shimamura T, Shiroishi M, Weyand S, et al. Structure of the human histamine H1 receptor complex with doxepin. Nature 2011; 475: 65-70.
Parmentier R, Zhao Y, Perier M, et al. Role of histamine H1-receptor on behavioral states and wake maintenance during deficiency of a brain activating system: a study using a knockout mouse model. Neuropharmacology 2016; 106: 20-34.
Akdis CA, Simons FE. Histamine receptors are hot in immunopharmacology. Eur J Pharmacol 2006; 533: 69-76.
Oda T, Morikawa N, Saito Y, et al. Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes. J Biol Chem 2000; 275: 36781-6.
Rzodkiewicz P, Wojtecka-Łukasik E, Maśliński S. Role of histamine in rheumatoid diseases. Reumatologia 2010; 48: 49-53.
Jutel M, Watanabe T, Klunker S, et al. Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors. Nature 2001; 413: 420-5.
Sallusto F, Lanzavecchia A. The instructive role of dendritic cells on T-cell responses. Arthritis Res 2002; 4 Suppl 3: S127-32.
Salcedo C, Pontes C, Merlos M. Is the H4 receptor a new drug target for allergies and asthma? Front Biosci (Elite Ed) 2013; 5: 178-87.
Dontchev VD, Letourneau PC. Nerve growth factor and semaphorin 3A signaling pathways interact in regulating sensory neuronal growth cone motility. J Neurosci 2002; 22: 6659-69.
Takamatsu H, Takegahara N, Nakagawa Y, et al. Semaphorins guide the entry of dendritic cells into the lymphatics by activating myosin II. Nat Immunol 2010; 11: 594-600.
Ohsawa Y, Hirasawa N. The role of histamine H1 and H4 receptors in atopic dermatitis: from basic research to clinical study. Allergol Int 2014; 63: 533-42.
Tominaga M, Takamori K. Sensitization of itch signaling: itch sensitization – nerve growth factor, semaphorins. In: Itch: Mechanisms and Treatment. Carstens E, Akiyama T (eds). CRC Press/Taylor & Francis; Boca Raton (FL) 2014; chapter 17.
Zampeli E, Tiligada E. The role of histamine H4 receptor in immune and inflammatory disorders. Br J Pharmacol 2009; 157: 24-33.
Sakai O, Tamada Y, Shearer TR, Azuma M. Involvement of NFkappaB in the production of chemokines by rat and human conjunctival cells cultured under allergenic conditions. Curr Eye Res 2013; 38: 825-34.
Enríquez-de-Salamanca A, Calder V, Gao J, et al. Cytokine responses by conjunctival epithelial cells: an in vitro model of ocular inflammation. Cytokine 2008; 44: 160-7.
Leonardi A, Curnow SJ, Zhan H, Calder VL. Multiple cytokines in human tear specimens in seasonal and chronic allergic eye disease and in conjunctival fibroblast cultures. Clin Exp Allergy 2006; 36: 777-84.
Ohtsu H. Pathophysiologic role of histamine: evidence clarified by histidine decarboxylase gene knockout mice. Int Arch Allergy Immunol 2012; 158 (Suppl 1): 2-6.
Dunford PJ, O’Donnell N, Riley JP, et al. The histamine H4 receptor mediates allergic airway inflammation by regulating the activation of CD4+ T cells. J Immunol 2006; 176: 7062-70.
Church MK, Maurer M. Antihistamines. Chem Immunol Allergy 2014; 100: 302-10.
Doenicke A, Moss J, Toledano A, et al. Administration of H1 and H2 antagonists for chemoprophylaxis: a double-blind, placebo-controlled study in healthy volunteers. J Clin Pharmacol 1997; 37: 140-6.
Muraro A, Roberts G, Worm M, et al.; EAACI Food Allergy and Anaphylaxis Guidelines Group. Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology. Allergy 2014; 69: 1026-45.
Runge JW, Martinez JC, Caravati EM, et al. Histamine antagonists in the treatment of acute allergic reactions. Ann Emerg Med 1992; 21: 237-242.
Lin RY, Curry A, Pesola GR, et al. Improved outcomes in patients with acute allergic syndromes who are treated with combined H1 and H2 antagonists. Ann Emerg Med 2000; 36: 462-8.
Tramer MR, von Elm E, Loubeyre P, Hauser C. Pharmacological prevention of serious anaphylactic reactions due to iodinated contrast media: systematic review. BMJ 2006; 333: 675-681.
Brockow K, Ring J. Anaphylaxis to radiographic contrast media. Curr Opin Allergy Clin Immunol 2011; 11: 326-31.
Klein PA, Clark RAF. An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. Arch Dermatol 1999; 135: 1522-5.
Akdis CA, Akdis M, Bieber T, et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL consensus report. J Allergy Clin Immunol 2006; 118: 152-169.
Saeki H, Furue M, Furukawa F, et al. Guidelines for management of atopic dermatitis. J Dermatol 2009; 36: 563-577.
Thurmond RL. The histamine H4 receptor: from orphan to the clinic. Front Pharmacol 2015; 6: 65.
Metz M, Ständer S. Chronic pruritus: pathogenesis, clinical aspects and treatment. J Eur Acad Dermatol Venereol 2010; 24: 1249-60.
Gantz I, Schäffer M, DelValle J, et al. Molecular cloning of a gene encoding the histamine H2 receptor. Proc Natl Acad Sci USA 1991; 88: 429-33. Erratum in: Proc Natl Acad Sci USA 1991; 88: 5937.
Haas HL, Panula P. Histamine receptors. Neuropharmacology 2016; 106: 1-2.
Bongers G, Sallmen T, Passani MB, et al. The Akt/GSK-3beta axis as a new signaling pathway of the histamine H(3) receptor. J Neurochem 2007; 103: 248-58.
Bitner RS, Markosyan S, Nikkel AL, Brioni JD. In-vivo histamine H3 receptor antagonism activates cellular signaling suggestive of symptomatic and disease modifying efficacy in Alzheimer’s disease. Neuropharmacology 2011; 60: 460-6.
Haas H, Panula P. The role of histamine and the tuberomamillary nucleus in the nervous system. Nat Rev Neurosci 2003; 4: 121-30.
Lovenberg TW, Roland BL, Wilson SJ, et al. Cloning and functional expression of the human histamine H3 receptor. Mol Pharmacol 1999; 55: 1101-7.
Anichtchik OV, Peitsaro N, Rinne JO, et al. Distribution and modulation of histamine H(3) receptors in basal ganglia and frontal cortex of healthy controls and patients with Parkinson’s disease. Neurobiol Dis 2001; 8: 707-16.
Karlstedt K, Ahman MJ, Anichtchik OV, et al. Expression of the H3 receptor in the developing CNS and brown fat suggests novel roles for histamine. Mol Cell Neurosci 2003; 24: 614-22.
Héron A, Rouleau A, Cochois V, et al. Expression analysis of the histamine H3 receptor in developing rat tissues. Mech Dev 2001; 105: 167-73.
Grandi D, Shenton FC, Chazot PL, Morini G. Immunolocalization of histamine H3 receptors on endocrine cells in the rat gastrointestinal tract. Histol Histopathol 2008; 23: 789-98.
Imamura M, Smith NC, Garbarg M, Levi R. Histamine H3-receptor-mediated inhibition of calcitonin gene-related peptide release from cardiac C fibers. A regulatory negative-feedback loop. Circ Res 1996; 78: 863-9.
Yamasaki T, Tamai I, Matsumura Y. Activation of histamine H3 receptors inhibits renal noradrenergic neurotransmission in anesthetized dogs. Am J Physiol Regul Integr Comp Physiol 2001; 280: R1450-6.
Ichinose M, Barnes PJ. Histamine H3 receptors modulate antigen-induced bronchoconstriction in guinea pigs. J Allergy Clin Immunol 1990; 86: 491-5.
Ohkubo T, Shibata M. ATP-sensitive K+ channels mediate regulation of substance P release via the prejunctional histamine H3 receptor. Eur J Pharmacol 1995; 277: 45-9.
Matsubara T, Moskowitz MA, Huang Z. UK-14,304, R(2)-alpha-methyl-histamine and SMS 201-995 block plasma protein leakage within dura mater by prejunctional mechanisms. Eur J Pharmacol 1992; 224: 145-50.
Jókúti A, Hellinger E, Hellinger A. Histamine H4 receptor expression is elevated in human nasal polyp tissue. Cell Biol Int 2007; 31: 1367-70.
Werner K, Neumann D, Buschauer A, Seifert R. No evidence for histamine H4 receptor in human monocytes. J Pharmacol Exp Ther 2014; 351: 519-26.
Zhu J, Qu C, Lu X, Zhang S. Activation of microglia by histamine and substance P. Cell Physiol Biochem 2014; 34: 768-80.
Suzuki S, Takeuchi K, Majima Y. Localization and function of histamine H3 receptor in the nasal mucosa. Clin Exp Allergy 2008; 38: 1476-82.
Yokota E, Kuyama S, Sugimoto Y, et al. Participation of histamine H3 receptors in experimental allergic rhinitis of mice. J Pharmacol Sci 2008; 108: 206-11.
Slack RJ, Russell LJ, Hall DA, et al. Pharmacological characterization of GSK1004723, a novel, long-acting antagonist at histamine H(1) and H(3) receptors. Br J Pharmacol 2011; 164: 1627-41.
Taylor-Clark T, Sodha R, Warner B, Foreman J. Histamine receptors that influence blockage of the normal human nasal airway. Br J Pharmacol 2005; 144: 867-74.
McLeod RL, Rizzo CA, West Jr RE, et al. Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N’-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687). J Pharmacol Exp Ther 2003; 305: 1037-44.
Varty LM, Hey JA. Histamine H3 receptor activation inhibits neurogenic sympathetic vasoconstriction in porcine nasal mucosa. Eur J Pharmacol 2002; 452: 339-45.
Hirasawa N, Ohuchi K. Roles of histamine in the exacerbated allergic dermatitis [Japanese]. Yakugaku Zasshi 2011; 131: 179-84.
Hirasawa N, Ohsawa Y, Katoh G, et al. Modification of the picryl chloride-induced allergic dermatitis model in mouse ear lobes by 12-O-tetradecanoylphorbol 13-acetate, and analysis of the role of histamine in the modified model. Int Arch Allergy Immunol 2009; 148: 279-88.
Ehling S, Roßbach K, Dunston SM, et al. Allergic inflammation is augmented via histamine H4 receptor activation: the role of natural killer cells in vitro and in vivo. J Dermatol Sci 2016; 83: 106-15.
Grosicki M, Kieć-Kononowicz K. Human eosinophils – potential pharmacological model applied in human histamine H4 receptor research. Curr Med Chem 2015; 22: 2087-99.
del Rio R, Noubade R, Saligrama N, et al. Histamine H4 receptor optimizes T regulatory cell frequency and facilitates anti-inflammatory responses within the central nervous system. J Immunol 2012; 188: 541-7.
Hsieh GC, Chandran P, Salyers AK, et al. H4 receptor antagonism exhibits anti-nociceptive effects in inflammatory and neuropathic pain models in rats. Pharmacol Biochem Behav 2010; 95: 41-50.
Miadonna A, Milazzo N, Gibelli S, et al. Nasal response to a single antigen challenge in patients with allergic rhinitis – inflammatory cell recruitment persists up to 48 hours. Clin Exp Allergy 1999; 29: 941-9.
Thomas M, Edwards MJ, Sawicka E, et al. Essential role of phosphoinositide 3-kinase gamma in eosinophil chemotaxis within acute pulmonary inflammation. Immunology 2009; 126: 413-22.
Ling P, Ngo K, Nguyen S, et al. Histamine H4 receptor mediates eosinophil chemotaxis with cell shape change and adhesion molecule upregulation. Br J Pharmacol 2004; 142: 161-71.
Shin N, Covington M, Bian D, et al. INCB38579, a novel and potent histamine H4 receptor small molecule antagonist with anti-inflammatory pain and anti-pruritic functions. Eur J Pharmacol 2012; 675: 47-56.
Strakhova MI, Cuff CA, Manelli AM, et al. In vitro and in vivo characterization of A-940894: a potent histamine H4 receptor antagonist with antiinflammatory properties. Br J Pharmacol 2009; 157: 44-54.
Reher TM, Neumann D, Buschauer A, Seifert R. Incomplete activation of human eosinophils via the histamine H4-receptor: evidence for ligand-specific receptor conformations. Biochem Pharmacol 2012; 84: 192-203.
Sabroe I, Hartnell A, Jopling LA, et al. Differential regulation of eosinophil chemokine signaling via CCR3 and non-CCR3 pathways. J Immunol 1999; 162: 2946-55.
Lim HD, van Rijn RM, Ling P, et al. Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist. J Pharmacol Exp Ther 2005; 314: 1310-21.
Thurmond RL, Chen B, Dunford PJ, et al. Clinical and preclinical characterization of the histamine H4 receptor antagonist JNJ-39758979. J Pharmacol Exp Ther 2014; 349: 176-84.
Yu F, Wolin RL, Wei J, et al. Pharmacological characterization of oxime agonists of the histamine H4 receptor. J Receptor Ligand Channel Res 2010; 3: 37-49.
Mirzahosseini A, Dalmadi B, Csutora P. Histamine receptor H4 regulates mast cell degranulation and IgE induced FcepsilonRI upregulation in murine bone marrow-derived mast cells. Cell Immunol 2013; 283: 38-44.
Thurmond RL, Desai PJ, Dunford PJ, et al. A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties. J Pharmacol Exp Ther 2004; 309: 404-13.
Hofstra CL, Desai PJ, Thurmond RL, Fung-Leung WP. Histamine H4 receptor mediates chemotaxis and calcium mobilization of mast cells. J Pharmacol Exp Ther 2003; 305: 1212-21.
Desai P, Thurmond RL. Histamine H4 receptor activation enhances LPS-induced IL-6 production in mast cells via ERK and PI3K activation. Eur J Immunol 2011; 41: 1764-73.
Jemima EA, Prema A, Thangam EB. Functional characterization of histamine H4 receptor on human mast cells. Mol Immunol 2014; 62: 19-28.
Varga C, Horvath K, Berko A, et al. Inhibitory effects of histamine H4 receptor antagonists on experimental colitis in the rat. Eur J Pharmacol 2005; 522: 130-8.
Cowden JM, Riley JP, Ma JY, et al. Histamine H4 receptor antagonism diminishes existing airway inflammation and dysfunction via modulation of Th2 cytokines. Respir Res 2010; 11: 86.
Andersson C, Tufvesson E, Diamant Z, Bjermer L. Revisiting the role of the mast cell in asthma. Curr Opin Pulm Med 2016; 22: 10-7.
George L, Brightling CE. Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease. Ther Adv Chronic Dis 2016; 7: 34-51.
Metcalfe DD, Pawankar R, Ackerman SJ, et al. Biomarkers of the involvement of mast cells, basophils and eosinophils in asthma and allergic diseases. World Allergy Organ J 2016; 9: 7.
Dunford PJ, Holgate ST. The role of histamine in asthma. Adv Exp Med Biol 2010; 709: 53-66.
Beermann S, Glage S, Jonigk D, et al. Opposite effects of mepyramine on JNJ 7777120-induced amelioration of experimentally induced asthma in mice in sensitization and provocation. PLoS One 2012; 7: e30285.
Neumann D, Beermann S, Burhenne H, et al. The dual H3/4R antagonist thioperamide does not fully mimic the effects of the ‘standard’ H4R antagonist JNJ 7777120 in experimental murine asthma. Naunyn Schmiedebergs Arch Pharmacol 2013; 386: 983-90.
Cowden JM, Zhang M, Dunford PJ, Thurmond RL. The histamine H4 receptor mediates inflammation and pruritus in Th2-dependent dermal inflammation. J Invest Dermatol 2010; 130: 1023-33.
Seike M, Furuya K, Omura M, et al. Histamine H4 receptor antagonist ameliorates chronic allergic contact dermatitis induced by repeated challenge. Allergy 2010; 65: 319-26.
Matsushita A, Seike M, Okawa H, et al. Advantages of histamine H4 receptor antagonist usage with H1 receptor antagonist for the treatment of murine allergic contact dermatitis. Exp Dermatol 2012; 21: 714-5.
Ohsawa Y, Hirasawa N. The antagonism of histamine H1 and H4 receptors ameliorates chronic allergic dermatitis via anti-pruritic and anti-inflammatory effects in NC/Nga mice. Allergy 2012; 67: 1014-22.
Mahapatra S, Albrecht M, Behrens B, et al. Delineating the role of histamine-1- and -4-receptors in a mouse model of Th2-dependent antigen-specific skin inflammation. PLoS One 2014; 9: e87296.
Bryce PJ, Mathias CB, Harrison KL, et al. The H1 histamine receptor regulates allergic lung responses. J Clin Invest 2006; 116: 1624-32.
Morgan RK, McAllister B, Cross L, et al. Histamine 4 receptor activation induces recruitment of FoxP3+ T cells and inhibits allergic asthma in a murine model. J Immunol 2007; 178: 8081-9.
Gutzmer R, Mommert S, Gschwandtner M, et al. The histamine H4 receptor is functionally expressed on TH2 cells. J Allergy Clin Immunol 2009; 123: 619-25.
Makala LH, Nagasawa H. Dendritic cells: a specialized complex system of antigen presenting cells. J Vet Med Sci 2002; 64: 181-93.
Gutzmer R, Diestel C, Mommert S, et al. Histamine H4 receptor stimulation suppresses IL-12p70 production and mediates chemotaxis in human monocyte-derived dendritic cells. J Immunol 2005; 174: 5224-32.
Damaj BB, Becerra CB, Esber HJ, et al. Functional expression of H4 histamine receptor in human natural killer cells, monocytes, and dendritic cells. J Immunol 2007; 179: 7907-15.
Bäumer W, Wendorff S, Gutzmer R, et al. Histamine H4 receptors modulate dendritic cell migration through skin – immunomodulatory role of histamine. Allergy 2008; 63: 1387-94.
Gschwandtner M, Rossbach K, Dijkstra D, et al. Murine and human Langerhans cells express a functional histamine H4 receptor: modulation of cell migration and function. Allergy 2010; 65: 840-9.
Gschwandtner M, Mommert S, Koether B, et al. The histamine H4 receptor is highly expressed on plasmacytoid dendritic cells in psoriasis and histamine regulates their cytokine production and migration. J Invest Dermatol 2011; 131: 1668-76.
Dijkstra D, Stark H, Chazot PL, et al. Human inflammatory dendritic epidermal cells express a functional histamine H4 receptor. J Invest Dermatol 2008; 128: 1696-703.
Gschwandtner M, Bunk H, Koether B, et al. Histamine down-regulates IL-27 production in antigen-presenting cells. J Leukoc Biol 2012; 92: 21-9.
Wang M, Han J, Domenico J, Shin YS, Jia Y, Gelfand EW. Combined blockade of the histamine H1 and H4 receptor suppresses peanut-induced intestinal anaphylaxis by regulating dendritic cell function. Allergy 2016; 71: 1561-74.
Cowden JM, Yu F, Banie H, et al. The histamine H4 receptor mediates inflammation and Th17 responses in preclinical models of arthritis. Ann Rheum Dis 2014; 73: 600-8.
Savall BM, Chavez F, Tays K, et al. Discovery and SAR of 6-alkyl-2,4-diaminopyrimidines as H4 receptor antagonists. J Med Chem 2014; 57: 2429-39.
Mommert S, Gschwandtner M, Koether B, et al. Human memory Th17 cells express a functional histamine H4 receptor. Am J Pathol 2012; 180: 177-85.
Ballerini C, Aldinucci A, Luccarini I, et al. Antagonism of histamine H4 receptors exacerbates clinical and pathological signs of experimental autoimmune encephalomyelitis. Br J Pharmacol 2013; 170: 67-77.
Bell JK, McQueen DS, Rees JL. Involvement of histamine H4 and H1 receptors in scratching induced by histamine receptor agonists in BalbC mice. Br J Pharmacol 2004; 142: 374-80.
Dunford PJ, Williams KN, Desai PJ, et al. Histamine H4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus. J Allergy Clin Immunol 2007; 119: 176-83.
Yamaura K, Oda M, Suwa E, et al. Expression of histamine H4 receptor in human epidermal tissues and attenuation of experimental pruritus using H4 receptor antagonist. J Toxicol Sci 2009; 34: 427-31.
Cowart MD, Altenbach RJ, Liu H, et al. Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models. J Med Chem 2008; 51: 6547-57.
Liu H, Altenbach RJ, Carr TL, et al. Cis-4-(piperazin-1-yl)- 5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quina zolin-2-amine (A 987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia. J Med Chem 2008; 51: 7094-98.
Koenig JR, Liu H, Drizin I, et al. Rigidified 2-aminopyrimidines as histamine H4 receptor antagonists: effects of substitution about the rigidifying ring. Bioorg Med Chem Lett 2010; 20: 1900-4.
Rossbach K, Wendorff S, Sander K, et al. Histamine H4 receptor antagonism reduces hapten-induced scratching behaviour but not inflammation. Exp Dermatol 2009; 18: 57-63.
Suwa E, Yamaura K, Oda M, et al. Histamine H4 receptor antagonist reduces dermal inflammation and pruritus in a hapten-induced experimental model. Eur J Pharmacol 2011; 667: 383-8.
Sadek B, Stark H. Cherry-picked ligands at histamine receptor subtypes. Neuropharmacology 2016; 106: 56-73.
Somma T, Cinci L, Formicola G, et al. A selective antagonist of histamine H4 receptors prevents antigen-induced airway inflammation and bronchoconstriction in guinea pigs: involvement of lipocortin-1. Br J Pharmacol 2013; 170: 200-13.
Bäumer W, Stahl J, Sander K, et al. Lack of preventing effect of systemically and topically administered histamine H1 or H4 receptor antagonists in a dog model of acute atopic dermatitis. Exp Dermatol 2011; 20: 577-81.
Rosa AC, Pini A, Lucarini L, et al. Prevention of bleomycin-induced lung inflammation and fibrosis in mice by naproxen and JNJ7777120 treatment. J Pharmacol Exp Ther 2014; 351: 308-16.
Liu WL. Histamine H4 receptor antagonists for the treatment of inflammatory disorders. Drug Discov Today 2014; 19: 1222-5.
Hisamichi K, Murata Y, Song M et al. A randomized, placebo-controlled study of H4R antagonist, JNJ-39758979, in atopic dermatitis. Abstract P-279. The 25th Spring Meeting of Japanese Society of Allergology 2013, Yokohama, Japan. Arerugi [Japanese Journal of Allergology] 2013; 62: 456.
Kollmeier A, Francke K, Chen B, et al. The histamine H4 receptor antagonist, JNJ 39758979, is effective in reducing histamine-induced pruritus in a randomized clinical study in healthy subjects. J Pharmacol Exp Ther 2014; 350: 181-7.
Murata Y, Song M, Kikuchi H, et al. Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of a H4R-antagonist (JNJ-39758979) in Japanese adults with moderate atopic dermatitis.
J Dermatol 2015; 42: 129-39.
Bäumer W, Glatzer F, Roßbach K, et al. Histamine in atopic disorders: atopic dermatitis and pruritus. In: Histamine H4 Receptor a Novel Drug Target For Immunoregulation and Inflammation. H. Stark (eds). De Gruytner 2013; 173-99.
Chigbu DI, Coyne AM. Update and clinical utility of alcaftadine ophthalmic solution 0.25% in the treatment of allergic conjunctivitis. Clin Ophthalmol 2015; 9: 1215-25.
Namdar R, Valdez C. Alcaftadine: a topical antihistamine for use in allergic conjunctivitis. Drugs Today (Barc) 2011; 47: 883-90.
Gallois-Bernos AC, Thurmond RL. Alcaftadine, a new antihistamine with combined antagonist activity at histamine H1, H2, and H4 receptors. J Recept Ligand Channel Res 2012; 5: 9-20.
Nakano Y, Takahashi Y, Ono R, et al. Role of histamine H4 receptor in allergic conjunctivitis in mice. Eur
J Pharmacol 2009; 608: 71-5.
Coruzzi G, Adami M, Guaita E, et al. Antiinflammatory and antinociceptive effects of the selective histamine H4-receptor antagonists JNJ7777120 and VUF6002 in a rat model of carrageenan-induced acute inflammation. Eur J Pharmacol 2007; 563: 240-4.
Altenbach RJ, Adair RM, Bettencourt BM, et al. Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands. J Med Chem 2008; 51: 6571-80.
Strakhova MI, Nikkel AL, Manelli AM, et al. Localization of histamine H4 receptors in the central nervous system of human and rat. Brain Res 2009; 1250: 41-8.
Cianchi F, Cortesini C, Schiavone N, et al. The role of cyclooxygenase-2 in mediating the effects of histamine on cell proliferation and vascular endothelial growth factor production in colorectal cancer. Clin Cancer Res 2005; 11: 6807-15.
Takahashi Y, Kagawa Y, Izawa K, et al. Effect of histamine H4 receptor antagonist on allergic rhinitis in mice. Int Immunopharmacol 2009; 9: 734-8.
Yan ZQ, Zhang RX, Yu SQ, et al. Effect of histamine H4 receptor and its antagonist on allergic rhinitis in rats [Chinese]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2010; 45: 477-80.
Hartwig C, Munder A, Glage S, et al. The histamine H4-receptor (H4R) regulates eosinophilic inflammation in ovalbumin-induced experimental allergic asthma in mice. Eur J Immunol 2015; 45: 1129-40.
Ridolo E, Montagni M, Melli V, et al. Pharmacotherapy of allergic rhinitis: current options and future perspectives. Expert Opin Pharmacother 2014; 15: 73-83.
Albu S, Nagy A, Doros C, et al. Treatment of Meniere’s disease with intratympanic dexamethazone plus high dosage of betahistine. Am J Otolaryngol 2016; 37: 225-30.
Seemungal B, Kaski D, Lopez-Escamez JA. Early diagnosis and management of acute vertigo from vestibular migraine and Ménière’s disease. Neurol Clin 2015; 33: 619-28.
Wakix. Pitolisant. [Author(s) not stated]. European Medicines Agency. Human medicines. Page last updated on April 13rd, 2016. URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002616/human_med_001955.jsp&mid=WC0b01ac058001d124 (last accessed on January 15, 2017).
Procopiou PA, Ancliff RA, Gore PM, et al. The discovery of quinoline based single-ligand human H1 and H3 receptor antagonists. Bioorg Med Chem Lett 2016; 26: 5855-9.
Nikolic K, Filipic S, Agbaba D, Stark H. Procognitive properties of drugs with single and multitargeting H3 receptor antagonist activities. CNS Neurosci Ther 2014; 20: 613-23.
Łażewska D, Kieć-Kononowicz K. New developments around histamine H(3) receptor antagonists/inverse agonists: a patent review (2010 - present). Expert Opin Ther Pat 2014; 24: 89-111.
Singh M, Jadhav HR. Histamine H3 receptor function and ligands: recent developments. Mini Rev Med Chem 2013; 13: 47-57.
Bhowmik M, Khanam R, Vohora D. Histamine H3 receptor antagonists in relation to epilepsy and neurodegeneration: a systemic consideration of recent progress and perspectives. Br J Pharmacol 2012; 167: 1398-414.
Wager TT, Pettersen BA, Schmidt AW, et al. Discovery of two clinical histamine H(3) receptor antagonists: trans-N-ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidinylmethyl)phenyl]cyclobutanecarboxamide (PF-03654746) and trans-3-fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]-N-(2-methylpropyl) cyclobutanecarboxamide (PF-03654764). J Med Chem 2011; 54: 7602-20.
Stokes JR, Romero FA Jr, Allan RJ, et al. The effects of an H3 receptor antagonist (PF-03654746) with fexofenadine on reducing allergic rhinitis symptoms. J Allergy Clin Immunol 2012; 129: 409-12.
North ML, Walker TJ, Steacy LM, et al. Add-on histamine receptor-3 antagonist for allergic rhinitis: a double blind randomized crossover trial using the environmental exposure unit. Allergy Asthma Clin Immunol 2014; 10: 33.
Barchuk WT, Salapatek AM, Ge T, et al. A proof-of-concept study of the effect of a novel H3-receptor antagonist in allergen-induced nasal congestion. J Allergy Clin Immunol 2013; 132: 838-46.e1-6.
Daley-Yates P, Ambery C, Sweeney L, et al. The efficacy and tolerability of two novel H(1)/H(3) receptor antagonists in seasonal allergic rhinitis. Int Arch Allergy Immunol 2012; 158: 84-98.
Norman P. New H1/H3 antagonists for treating allergic rhinitis: WO2010094643. Expert Opin Ther Pat 2011; 21: 425-9.
Procopiou PA, Browning C, Buckley JM, et al. The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis. J Med Chem 2011; 54; 2183-95.
Jablonowski JA, Grice CA, Chai W, et al. The first potent and selective non-imidazole human histamine H4 receptor antagonists. J Med Chem 2003; 46: 3957-60.
Levoin N, Labeeuw O, Billot X, et al. Discovery of nanomolar ligands with novel scaffolds for the histamine H4 receptor by virtual screening. Eur J Med Chem 2017; 5: 565-72.
Labeeuw O, Levoin N, Billot X, et al. Synthesis and evaluation of a 2-benzothiazolylphenylmethyl ether class of histamine H4 receptor antagonists. Bioorg Med Chem Lett 2016; 26: 5263-6.
McLaurin EB, Marsico NP, Ackerman SL, et al. Ocular itch relief with alcaftadine 0.25% versus olopatadine 0.2% in allergic conjunctivitis: pooled analysis of two multicenter randomized clinical trials. Adv Ther 2014; 31: 1059-71.
Williams HC. Clinical practice. Atopic dermatitis. N Engl J Med 2005; 352: 2314-24.
FEATURED PRODUCTS
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe